Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00860730
Other study ID # V10801
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2009
Est. completion date October 2015

Study information

Verified date January 2019
Source Corcym S.r.l
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The clinical investigation is designed as a prospective and non-randomised study on a maximum of 150 patients. This study will be conducted at Investigational Centres in the European Community. A minimum number of 8 European Centres will be involved in the clinical investigation. A minimum of 15 patients will be enrolled at each Investigational Centre. The clinical follow-up requires evaluations at discharge (or 30 days if the patient is still hospitalized), 3-6 and 12 months following the procedure.The primary objective of this clinical investigation is to assess the performance of the Perceval S valve at 3-6 months after implantation in high surgical risk patients, who require a surgical intervention to replace the aortic valve.


Description:

The design of the Perceval S prosthesis stems from the intention to offer an alternative to traditional flexible prostheses (stented and stentless biological valves) using conventional open-heart surgery. As a result of the sutureless implant procedure, in fact, patients could benefit from: Reducing aortic clamp times, with subsequent overall reduction of surgical timing and therefore reduction in related risks; Avoiding to pass the stitches through the annulus and sutures knotting, with consequent less risk of tearing aortic annulus and wall, damaging the bundle of His, embolizing foreign material in the vascular system.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date October 2015
Est. primary completion date October 2009
Accepts healthy volunteers No
Gender All
Age group 75 Years and older
Eligibility Inclusion Criteria: - Subjects of 75 years or older; - Subjects with aortic valve stenosis or steno-insufficiency; - Subjects at high surgical risk and candidates for aortic valve replacement with a biological prosthesis; - Subjects in NYHA functional classes III and IV with the Logistic EuroSCORE greater than 5%. - Subjects who have agreed to participation in the clinical evaluation and who have signed the informed consent; - Subjects who are willing to undergo all the medical follow-ups and echocardiographic examinations and laboratory tests that form part of this present protocol. Exclusion Criteria: - Subjects involved in any other clinical study for drugs or devices; - Subjects who have previously undergone implantation with the Perceval S prosthesis being assessed; - Subjects with previous implantation of valve prostheses or annuloplasty ring in mitral position; - Subjects requiring simultaneous procedures, apart from septal myectomy and/or coronary by-pass; - Subjects with aneurysmal dilation or dissection of the ascending aortic wall needing surgical correction; - Subjects needing non elective intervention; - Subjects with aortic annulus (after procedure for decalcification) of dimensions such that the implantation of a valve of size 21 or 23 mm is not possible (direct intra-operative measurement with sizer), in accordance with the indications reported in the Investigator's Brochure; - Subjects with active endocarditis; - Subjects with active myocarditis; - Subjects with any anomaly of the coronary ostia determined through pre-operative coronary angiogram or during intervention itself; - Subjects with congenital bicuspid aortic valve; - Subjects with aortic root enlargement, where the ratio between observed and expected diameters (calculated as a function of age and patient body surface area) is > 1.3; - Subjects with aortic root enlargement, where the ratio between the diameter of the sino-tubular junction and the annulus diameter is > 1.3; - Subjects with myocardial infarct < =90 days; - Subjects with known hypersensitivity to nickel alloys.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Aortic valve replacement with Perceval aortic heart valve
Replacement of diseased or malfunctioning native aortic valve via traditional surgery (open chest) with the Perceval S prosthesis

Locations

Country Name City State
Belgium UZ Leuven Leuven
France CHRU de Lille Lille
France Hopital Guillaume et René Laennec Nantes
France Institut Mutualiste Montsouris Paris
France Hôpital Cardiologique du Haut-Lévêque Pessac
Germany Ruhr Universität Bochum Bochum
Germany Westdeutsches Herzzentrum Essen
Germany Medizinische Hochschule Hannover Hannover
Switzerland Inselspital Bern Bern

Sponsors (1)

Lead Sponsor Collaborator
Corcym S.r.l

Countries where clinical trial is conducted

Belgium,  France,  Germany,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of the safety of the Perceval S prosthesis in terms of percentage incidence of mortality and morbidity at 3-6 months after implant 6 months
Secondary Assessment of mortality and morbidity rates at discharge (or 30 days if the patient is still hospitalized) and 12 months after implant 12 months
See also
  Status Clinical Trial Phase
Completed NCT00774293 - Homoeopathic Association in Aortic Valve Surgery Phase 4
Completed NCT05107453 - Serratus Anterior Plane Block for Minimal Invasive Cardiac Surgery Phase 4
Completed NCT01651780 - Open-label, Randomized Trial in Patients Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH Phase 3
Completed NCT01187329 - The Effect of the Hyperinsulinemic Normoglycemic Clamp on Myocardial Function and Utilization of Glucose N/A
Recruiting NCT05295628 - Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR N/A
Terminated NCT03680040 - RESILIENCE Trial: Evaluation of the Durability of Aortic Bioprostheses/Valves With RESILIA Tissue in Subjects Under 65
Recruiting NCT05539937 - Prospective Evaluation of the Quality of Life of Elderly Patients Undergoing Transfemoral Percutanous Aortic Valve Replacement (TAVI) for the Treatment of Severe Aortic Stenosis.
Recruiting NCT01522352 - Comparison Between Three Types of Stented Pericardial Aortic Valves N/A
Completed NCT01554709 - Safety and Performance Study of the CardioGard Cannula Phase 2/Phase 3
Suspended NCT04902053 - INSPIRIS RESILIA Aortic Valve, Valve-in-Valve Surveillance Study
Completed NCT01404975 - TAVI Protocol - Paravertebral Block Study N/A
Recruiting NCT03889288 - Innovative Device for Pain Management by Millimeter Band Radiation: Electronic-Pain Killer N/A
Active, not recruiting NCT05404880 - INSPIRIS China PMCF Study
Recruiting NCT04652375 - Outcomes After Albumin vs Lactated Ringer's Solution in CABG and AVR Procedures N/A
Recruiting NCT06106451 - Optimization Post-TAVR to IMprove Activity Levels (OPTIMAL Study) N/A
Active, not recruiting NCT00396760 - Comparison of Aprotinin and Tranexamic Acid in Routine Cardiac Surgery Phase 3
Not yet recruiting NCT03603483 - Aortic Root Enlargement in Aortic Valve Replacement N/A
Terminated NCT01368666 - Safety and Effectiveness Study of Perceval S Valve for Extended CE Mark N/A
Recruiting NCT03002272 - Transcatheter Aortic Prosthesis Function: A Long-term Follow-up Study
Active, not recruiting NCT03258333 - Small Aortic Annulus - a New Solution to the Old Problem N/A

External Links